The Aim of This Study is to Compare the Efficacy of Perioperative Hypertonic Saline 3% Versus Normal Saline (0.9%) in Decreasing Recurrence Risk in Non-muscle Invasive Bladder Cancer

PHASE2UnknownINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions

TCC

Interventions

DRUG

Hypertonic Saline

Hypertonic Saline 3% and 0.9%

Trial Locations (1)

RECRUITING

Kaplan MC, Rehovot